125 related articles for article (PubMed ID: 35963771)
1. Cost-Effectiveness of PET Directed Versus Combined Modality Therapy for Early-Stage Favorable Hodgkin's Lymphoma.
Smith CP; Adefres B; Chang EM; Huang TQ; Parikh N; Raldow A
Clin Lymphoma Myeloma Leuk; 2022 Nov; 22(11):e992-e999. PubMed ID: 35963771
[TBL] [Abstract][Full Text] [Related]
2. Metabolic tumor volume by positron emission tomography/computed tomography as a clinical parameter to determine therapeutic modality for early stage Hodgkin's lymphoma.
Song MK; Chung JS; Lee JJ; Jeong SY; Lee SM; Hong JS; Chong A; Moon JH; Kim JH; Lee SM; Kim SJ; Shin HJ
Cancer Sci; 2013 Dec; 104(12):1656-61. PubMed ID: 24033666
[TBL] [Abstract][Full Text] [Related]
3. Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group.
Fuchs M; Goergen H; Kobe C; Kuhnert G; Lohri A; Greil R; Sasse S; Topp MS; Schäfer E; Hertenstein B; Soekler M; Vogelhuber M; Zijlstra JM; Keller UB; Krause SW; Wilhelm M; Maschmeyer G; Thiemer J; Dührsen U; Meissner J; Viardot A; Eich H; Baues C; Diehl V; Rosenwald A; von Tresckow B; Dietlein M; Borchmann P; Engert A
J Clin Oncol; 2019 Nov; 37(31):2835-2845. PubMed ID: 31498753
[TBL] [Abstract][Full Text] [Related]
4. Is Radiation Therapy Cost-Effective in the Positron Emission Tomography/Computed Tomography Era for Early-Stage Favorable Hodgkin Lymphoma With Alternative Payment Models?
Kim H; Richman A; Smith KJ; Shaikh PM; Beriwal S; Vargo JA
Pract Radiat Oncol; 2022; 12(2):e135-e143. PubMed ID: 34902637
[TBL] [Abstract][Full Text] [Related]
5. Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET/CT is beneficial: a prospective multicentre trial of 355 patients.
Dann EJ; Bairey O; Bar-Shalom R; Mashiach T; Barzilai E; Kornberg A; Akria L; Tadmor T; Filanovsky K; Abadi U; Kagna O; Ruchlemer R; Abdah-Bortnyak R; Goldschmidt N; Epelbaum R; Horowitz NA; Lavie D; Ben-Yehuda D; Shpilberg O; Paltiel O
Br J Haematol; 2017 Sep; 178(5):709-718. PubMed ID: 28589704
[TBL] [Abstract][Full Text] [Related]
6. Combined modality treatment: Outcome in patients with Hodgkin's lymphoma.
Yadav BS; Sharma SC; Malhotra P; Prakash G
J Cancer Res Ther; 2020; 16(1):1-6. PubMed ID: 32362601
[TBL] [Abstract][Full Text] [Related]
7. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group.
Meyer RM; Gospodarowicz MK; Connors JM; Pearcey RG; Bezjak A; Wells WA; Burns BF; Winter JN; Horning SJ; Dar AR; Djurfeldt MS; Ding K; Shepherd LE; ;
J Clin Oncol; 2005 Jul; 23(21):4634-42. PubMed ID: 15837968
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of first-line treatment options for patients with advanced-stage Hodgkin lymphoma: a modelling study.
Vijenthira A; Chan K; Cheung MC; Prica A
Lancet Haematol; 2020 Feb; 7(2):e146-e156. PubMed ID: 31948928
[TBL] [Abstract][Full Text] [Related]
9. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial.
Engert A; Franklin J; Eich HT; Brillant C; Sehlen S; Cartoni C; Herrmann R; Pfreundschuh M; Sieber M; Tesch H; Franke A; Koch P; de Wit M; Paulus U; Hasenclever D; Loeffler M; Müller RP; Müller-Hermelink HK; Dühmke E; Diehl V
J Clin Oncol; 2007 Aug; 25(23):3495-502. PubMed ID: 17606976
[TBL] [Abstract][Full Text] [Related]
10. [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma].
Niu Y; Shi YK; He XH; Feng FY; Zhou LQ; Gu DZ
Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):630-4. PubMed ID: 19102946
[TBL] [Abstract][Full Text] [Related]
11. ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma.
Meyer RM; Gospodarowicz MK; Connors JM; Pearcey RG; Wells WA; Winter JN; Horning SJ; Dar AR; Shustik C; Stewart DA; Crump M; Djurfeldt MS; Chen BE; Shepherd LE; ;
N Engl J Med; 2012 Feb; 366(5):399-408. PubMed ID: 22149921
[TBL] [Abstract][Full Text] [Related]
12. An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma.
Hay AE; Klimm B; Chen BE; Goergen H; Shepherd LE; Fuchs M; Gospodarowicz MK; Borchmann P; Connors JM; Markova J; Crump M; Lohri A; Winter JN; Dörken B; Pearcey RG; Diehl V; Horning SJ; Eich HT; Engert A; Meyer RM;
Ann Oncol; 2013 Dec; 24(12):3065-9. PubMed ID: 24121121
[TBL] [Abstract][Full Text] [Related]
13. Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced high-risk Hodgkin's lymphoma.
Avigdor A; Bulvik S; Levi I; Dann EJ; Shemtov N; Perez-Avraham G; Shimoni A; Nagler A; Ben-Bassat I; Polliack A
Ann Oncol; 2010 Jan; 21(1):126-32. PubMed ID: 19608615
[TBL] [Abstract][Full Text] [Related]
14. PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial.
Borchmann P; Plütschow A; Kobe C; Greil R; Meissner J; Topp MS; Ostermann H; Dierlamm J; Mohm J; Thiemer J; Sökler M; Kerkhoff A; Ahlborn M; Halbsguth TV; Martin S; Keller U; Balabanov S; Pabst T; Vogelhuber M; Hüttmann A; Wilhelm M; Zijlstra JM; Moccia A; Kuhnert G; Bröckelmann PJ; von Tresckow B; Fuchs M; Klimm B; Rosenwald A; Eich H; Baues C; Marnitz S; Hallek M; Diehl V; Dietlein M; Engert A
Lancet Oncol; 2021 Feb; 22(2):223-234. PubMed ID: 33539742
[TBL] [Abstract][Full Text] [Related]
15. The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study.
Agostinelli C; Gallamini A; Stracqualursi L; Agati P; Tripodo C; Fuligni F; Sista MT; Fanti S; Biggi A; Vitolo U; Rigacci L; Merli F; Patti C; Romano A; Levis A; Trentin L; Stelitano C; Borra A; Piccaluga PP; Hamilton-Dutoit S; Kamper P; Zaucha JM; Małkowski B; Kulikowski W; Tajer J; Subocz E; Rybka J; Steidl C; Broccoli A; Argnani L; Gascoyne RD; d'Amore F; Zinzani PL; Pileri SA
Lancet Haematol; 2016 Oct; 3(10):e467-e479. PubMed ID: 27692305
[TBL] [Abstract][Full Text] [Related]
16. Involved-Field Radiation Therapy Prevents Recurrences in the Early Stages of Hodgkin Lymphoma in PET-Negative Patients After ABVD Chemotherapy: Relapse Analysis of GHSG Phase 3 HD16 Trial.
Baues C; Goergen H; Fuchs M; Rosenbrock J; Celik E; Eich H; Kobe C; Voltin CA; Engert A; Borchmann P; Marnitz S
Int J Radiat Oncol Biol Phys; 2021 Nov; 111(4):900-906. PubMed ID: 34389407
[TBL] [Abstract][Full Text] [Related]
17. Post-ABVD/pre-radiotherapy (18)F-FDG-PET provides additional prognostic information for early-stage Hodgkin lymphoma: a retrospective analysis on 165 patients.
Ciammella P; Filippi AR; Simontacchi G; Buglione M; Botto B; Mangoni M; Iotti C; Merli F; Marcheselli L; Bisi G; Ricardi U; Versari A
Br J Radiol; 2016; 89(1061):20150983. PubMed ID: 27022777
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials.
Sasse S; Bröckelmann PJ; Goergen H; Plütschow A; Müller H; Kreissl S; Buerkle C; Borchmann S; Fuchs M; Borchmann P; Diehl V; Engert A
J Clin Oncol; 2017 Jun; 35(18):1999-2007. PubMed ID: 28418763
[TBL] [Abstract][Full Text] [Related]
19. Early-stage Hodgkin lymphoma outcomes after combined modality therapy according to the post-chemotherapy 5-point score: can residual pet-positive disease be cured with radiotherapy alone?
Milgrom SA; Pinnix CC; Chuang H; Oki Y; Akhtari M; Mawlawi O; Garg N; Gunther JR; Reddy JP; Smith GL; Rohren E; Hagemeister FB; Lee HJ; Fayad LE; Dong W; Osborne EM; Abou Yehia Z; Fanale M; Dabaja BS
Br J Haematol; 2017 Nov; 179(3):488-496. PubMed ID: 28832956
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcome of patients with early stage favorable Hodgkin lymphoma treated with ABVD × two cycles followed by FDG-PET/CT restaging and 20 Gy of involved-site radiotherapy.
Kamran SC; Jacene HA; Chen YH; Mauch PM; Ng AK
Leuk Lymphoma; 2018 Jun; 59(6):1384-1390. PubMed ID: 28937297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
